Article thumbnail

IL-33 at the Crossroads of Metabolic Disorders and Immunity

By Lei Tu and Lijing Yang

Abstract

As a cytokine in interleukin-1(IL-1) family, interleukin-33(IL-33) usually exists in the cytoplasm and cell nucleus. When the cells are activated or damaged, IL-33 can be secreted into extracellular and regulate the functions of various immune cells through binding to its specific receptor suppression of tumorigenicity 2 (ST2). Except regulating the function of immune cells including T cells, B cells, dendritic cells (DCs), macrophages, mast cells, and innate lymphoid cells, IL-33 also plays an important role in metabolic diseases and has received an increasing attention. This review summarizes the regulation of IL-33 on different immune cells in lipid metabolism, which will help to understand the pathology of abnormal lipid metabolic diseases, such as atherosclerosis and type 2 diabetes

Topics: IL-33, metabolism, diabetes, innate & adaptive immune response, ST2, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Publisher: Frontiers Media S.A.
Year: 2019
DOI identifier: 10.3389/fendo.2019.00026/full
OAI identifier: oai:doaj.org/article:0c026048e4144a7091f354ed927b652e
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1664-2392 (external link)
  • https://doaj.org/article/0c026... (external link)
  • https://www.frontiersin.org/ar... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.